A drug developed by a University of Virginia Health scientist has reversed paralysis and vision loss in a mouse model of multiple sclerosis, according to a report from Medical Xpress. The outcome is notable because existing MS therapies are designed to dampen future inflammatory attacks rather than restore neurological function that has already been lost.
The experimental compound appeared to not only halt disease progression but also repair damage in the animals, allowing recovery of motor and visual abilities. The findings suggest a possible shift in how MS might be treated—moving beyond prevention toward actual repair of the nervous system.
Because this is a single preclinical study, the results are encouraging but far from conclusive. The next steps would involve further safety and efficacy testing before any human trials could begin. No comparison with other experimental approaches is available from this source.